Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714569 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Phase 1 study of Dyslipidemias, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT02714569: Completed Phase 1 study of Dyslipidemias, sponsored by Eli Lilly and Company.
NCT02714569 is a Phase 1 study of Dyslipidemias that has completed, run by Eli Lilly and Company. The registered enrollment target is 60 participants, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02714569, a Phase 1 study of Dyslipidemias, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
Primary Outcome
Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Simvastatin
- DRUG Atorvastatin
- DRUG LY3202328
Study Locations (4)
Florida
- Clinical Pharmacology of Miami, Inc. - Miami
Kansas
- PRA Health Sciences - Lenexa
New Jersey
- PRA Health Sciences - Marlton
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 1 |
What the finished NCT02714569 record still lists
NCT02714569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02714569 reports a single indexed study location in Florida, Kansas, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02714569 about?
NCT02714569 is a clinical study titled "A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia". The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
What is the current status of trial NCT02714569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-03. Estimated completion is 2017-02-15.
What conditions does trial NCT02714569 study?
This clinical trial studies the following conditions: Dyslipidemias.
What interventions are being tested in trial NCT02714569?
The interventions under investigation include: Placebo (DRUG), Simvastatin (DRUG), Atorvastatin (DRUG), LY3202328 (DRUG).
Who is sponsoring clinical trial NCT02714569?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02714569 being conducted?
This trial has 4 study locations across Florida, Kansas, New Jersey, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02714569's enrollment target sits among peer trials
60 21st of 28 higher than 8 of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
COMPLETED · Phase 1
-
A Study of LY3475766 in Healthy Participants
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia